



## WHO WE ARE

- ❖ Cornerstone Pharmaceuticals is a privately held, clinical-stage, metabolic oncology therapeutics company
- ❖ Our vision is to be the premier cancer metabolism company designing drugs to attack the proteins and enzymes reconfigured and repurposed in cancer and responsible for the tumor's anabolic and catabolic processes


## ALTERED ENERGY METABOLISM DIRECTED (AEMD) PLATFORM

- ❖ Targets altered regulation of metabolic processes specific to cancer cells
- ❖ Highly specific, simultaneously attack multiple targets, minimally toxic and have broad spectrum activity across wide variety of cancers
- ❖ Potential therapeutic options for difficult to treat cancers
- ❖ Because of very low toxicity, can be used in chronic dosing and can be used in combination with current standards of care with minimal additional toxicity
- ❖ Novel chemical class, compositions of matter and formulations protected until 2028 across US, Canada, EU, Australia and major Asian markets (China, Hong Kong, Japan, South Korea, Taiwan)

## CPI-613

- ❖ Currently being evaluated in 15 Phase I to Phase II trials as a single agent, as well as in combination with standard drug therapy for hematological malignancies and solid tumors
- ❖ To date, over 290 subjects have received one or more doses of CPI-613 and the drug exhibited good signals of efficacy with an excellent response rate and extended duration of response in several tumor types
- ❖ In pancreatic cancer, CPI-613 in combination with modified FOLFIRINOX exhibited 61% Objective Response Rate and 78% Clinical Benefit Rate
- ❖ In acute myeloid leukemia patients with poor cytogenetic risk, CPI-613 in combination with high dose cytarabine and mitoxantrone exhibited 38% Complete Response Rate
- ❖ In both these trials, the efficacy of CPI-613 combinations was substantially higher than standard therapy
- ❖ In peripheral T-cell lymphoma, CPI-613 in combination with Bendamustine exhibited signals of efficacy
- ❖ CPI-613 also showed very good safety profile both as single agent and in combination with other standard-of-care drugs
- ❖ CPI-613 has been granted U.S. orphan drug designation for MDS, AML and Pancreatic Cancer

## SUSTAINABLE GROWTH POTENTIAL



**FDA Clears Way for Pivotal Trials in Acute Myeloid Leukemia (AML) and Pancreatic Cancer**

**15 Ongoing or Completed Clinical Trials in Multiple Hematological Malignancies & Solid Tumors**

### Recent Conference Presentations:

- ASH 2015, ASH 2016 (AML)
- GCS 2016 (Pancreatic Cancer)
- ASH 2016 (T-cell Lymphoma)

## EXPERIENCED LEADERSHIP TEAM

- **Howard S. Jonas** Chairman of the Board
- **Robert G. L. Shorr, PhD, DIC** Chief Scientific Officer
- **David Polinsky** President and General Counsel
- **Sanjeev Luther** Chief Operating Officer
- **Paul Bingham PhD** VP, Research
- **Timothy S. Pardee, MD, PhD** Chief Oncologist

## KEY ADVISORY BOARD MEMBERS

### SCIENTIFIC ADVISORY BOARD:

- **Chi Van Dang, M.D., Ph.D.**
- **Dafna Bar-Sagi, Ph.D.**
- **Navdeep S. Chandel, Ph.D.**
- **Alec Kimmelman, M.D., Ph.D.**
- **Gregg Semenza, M.D., Ph.D.**

### MEDICAL ADVISORY BOARD:

- **Philip A. Philip, M.D., Ph.D., F.R.C.P.**
- **Jorge Cortes, M.D.**
- **Craig H. Moskowitz, M.D.**
- **Ariela Noy, MD**